[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596575":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":43,"collaborators":47,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":23,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":26,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":26,"overallStatus":70,"whyStopped":26,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University of Malaga","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"intervention","EXPERIMENTAL","A treatment with whole body red light therapy (NovoTHOR®) will be carried out",[13],"Device: PBM",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","A placebo whole body red light will be carried out",[19],"Other: Placebo PBM",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","PBM","A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo PBM","A placebo whole body red light will be carried out during 20 minutes",[15],[32],{"facility":33,"status":26,"city":34,"state":26,"zip":26,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":26},"Dr","Granada","Spain","ES",{"type":38,"coordinates":39},"Point",[40,41],-3.60667,37.18817,{"lat":41,"lon":40},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Daniel Aguilar Nunez","danunez",[48],{"name":49,"class":50},"clinical professor","UNKNOWN","100596575","short--and-long-term-effects-of-whole-body-photobiomodulation-in-type-ii-diabetes-patients-a-protocol-for-a-controlled-clinical-trial-100596575",false,"NCT07047248","Short- and Long-Term Effects of Whole-Body Photobiomodulation in Type II Diabetes Patients: A Protocol for a Controlled Clinical Trial","Inclusion Criteria:\n\n* Adults aged 30 to 70 years.\n* Diagnosed with Type 2 Diabetes Mellitus (T2DM) according to the American Diabetes Association (ADA) criteria.\n* HbA1c levels between 6.5% and 10% at screening.\n* Stable diabetes management regimen (medications and lifestyle) for at least three months prior to enrollment\n\nExclusion Criteria:\n\n* Presence of severe diabetic complications (e.g., end-stage renal disease, proliferative diabetic retinopathy).\n* History of photosensitivity or medical conditions exacerbated by light exposure.\n* Use of medications or supplements known to significantly alter glucose metabolism, other than current stable diabetes management.\n* Pregnant or lactating women.",true,"ALL","30 Years","70 Years",{"count":62,"type":63},44,"ESTIMATED","INTERVENTIONAL",[66],"NA","The development of an integral and global treatment to improve the quality of life in those withType II Diabetes Patients is challenging, thus a whole body Photobiomodulation (PBM) therapy program is proposed as an effective option.",[69],"Type II Diabetes Mellitus","NOT_YET_RECRUITING","2025-06-27",{"date":73,"type":74},"2025-07-02","ACTUAL",{"date":76,"type":63},"2025-08-30",{"date":78,"type":63},"2026-01-30",{"name":5,"class":6},1]